Microbot Medical signs manufacturing agreement with Sanmina for LIBERTY System

Microbot Medical Inc.

Entered into Letter of Agreement with Sanmina Corporation to manufacture the LIBERTY Endovascular Robotic System.
Agreement expands manufacturing capacity to meet rising demand from existing and new accounts in U.S. and internationally.
Expected to improve operating efficiencies, lower costs, and expand gross margins as part of cost reduction strategy.
Sanmina, a global manufacturing leader, provides second manufacturing site and potential for regional scaling.
Microbot plans to increase U.S. sales footprint to Western U.S. later this year; recent clearance in Israel, CE Mark progress.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.